Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

BAX vs LYRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BAX Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

BAX Overall Winner 6-Pillar Tally: BAX 6 – 0 LYRA Matrix Metrics: BAX 8 – 2 LYRA

As of Nov 17, 2026, Baxter International Inc. (BAX) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BAX carries a Unified Composite Score of 46.5/100 (HOLD) at $25.83 (12.5x Forward P/E, 7.6% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin).

  • Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. BAX 46.5/100 HOLD), BAX captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (7.6% vs. -25032.0% operating margin) and revenue trajectory (+5.0% vs. -87.2% YoY).
  • Technical & Structure Timing Caution: BAX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.2); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BAX vs LYRA
BAX NYSE Head-to-Head Winner
Baxter International Inc.
Surgical & Medical Instruments & Apparatus
$25.83
+1.14% 1D
Market Cap $13.4B
TTM Revenue $11.6B
Forward P/E 12.5x
Beta / 30D Vol 0.95β · 47% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 47.0 Fund 56.0 Flow 71.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.2 · SMA20: $25.38 · SMA50: $24.55
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
TTM Revenue $600,000
Forward P/E N/M
Beta / 30D Vol 0.33β · 248% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.3%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.27 · SMA50: $1.82

6-Pillar Scorecard Institutional Category Breakdown (BAX 6 – 0 LYRA)

Columns: Metric · BAX · LYRA
1. Valuation Multiples BAX
Forward P/E 12.5x N/M
Trailing P/E 12.2x N/M
PEG Ratio N/M N/M
EV / Revenue 1.7x 3.9x
2. Growth & Scale BAX
Revenue Growth (YoY) +5.0% -87.2%
Earnings Growth (YoY) +36.8% +0.0%
TTM Revenue (USD) $11.6B $600,000
Market Cap $13.4B $2.3M
3. Profitability & Quality BAX
Gross Margin 33.4% N/A
Operating Margin 7.6% -25032.0%
Net Profit Margin -6.2% 0.0%
Return on Equity (ROE) -9.0% -404.5%
4. Balance Sheet & Cash Flow BAX
Cash Generation (TTM) $1.13B -$32M EBITDA
Cash Flow Margin 9.8% N/A
Net Cash / Leverage $6.83B Net Debt (1.35x D/E) -404.5% ROE
Dividend Yield 0.16% None (0.00%)
5. Options & Positioning BAX
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 48.4% (5th %ile) N/A (N/A)
Put/Call OI Skew 0.15x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BAX
OpEx & R&D Intensity 25.8% of Rev ($3.00B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BAX (8) vs LYRA (2)
Institutional Metric BAX LYRA Criterion Row Edge
Market Capitalization
Scale
$13.4B $2.3M Larger Scale BAX
Trailing P/E Ratio
Valuation
12.2x N/M Lower Multiple BAX
Forward P/E Ratio
Valuation
12.5x N/M Lower Multiple BAX
Revenue Growth (YoY)
Growth
+5.0% -87.2% Higher Growth BAX
Operating Margin (TTM)
Profitability
7.6% -25032.0% Higher Margin BAX
Net Profit Margin
Profitability
-6.2% 0.0% Higher Margin LYRA
Return on Equity (ROE)
Capital Efficiency
-9.0% -404.5% Higher ROE BAX
52-Week Range Position
Momentum
71% ($16–$30) 1% ($0–$38) Stronger Trend BAX
Beta / 30D Volatility
Risk Regime
0.95β · 47% Vol 0.33β · 248% Vol Lower Realized Risk BAX
Unified Institutional Score
Composite Signal
46.5 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite LYRA
Trailing 12M Revenue (USD)
Operating Scale
$11.6B $600,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
33.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.7x EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.13B ($6.83B Net Debt (1.35x D/E)) -$32M EBITDA (-404.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BAX +53.79 pp
BAX: -8.71% · LYRA: -62.5%
3M Horizon BAX +77.99 pp
BAX: -9.63% · LYRA: -87.62%
6M Horizon BAX +79.61 pp
BAX: -7.53% · LYRA: -87.14%
1Y Horizon BAX +79.61 pp
BAX: -7.53% · LYRA: -87.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BAX Revenue LYRA Revenue BAX Op. Margin LYRA Op. Margin Margin Leader
FY2018 $11.1B N/A 14.3% N/A BAX
FY2019 $11.4B N/A 15.6% N/A BAX
FY2020 $11.7B N/A 13.8% N/A BAX
FY2021 $12.2B $0M 11.1% -15303.5% BAX
FY2022 $10.1B $0M -28.3% -4131.0% BAX
FY2023 $10.4B $0M 6.8% -4308.1% BAX
FY2024 $10.6B $0M 0.1% -6280.8% BAX
FY2025 $11.2B $0M -2.7% -7794.5% BAX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BAX CONSOLIDATION
74d in phase · OBV NEUTRAL
Current IV 48.4%
IV Percentile 5th %ile
Put/Call OI Skew 0.15x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BAX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LYRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $25.90 · IV 38.3%

BAX Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($2,590)

Compare $2,590 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 38.3% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $25 / $27.5 Bull Call Spread

Buy 1x $25C · Sell 1x $27.5C · 31d

Net Entry $111 Debit
T+5d @ +5% Move +$54 (+49%)
Max Risk / Buffer $111 Capped
5d Edge & Liquidity 0.9x R:R · Liq A
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq C

Nov 27 $26 / $24.5 Bear Put Spread

Buy 1x $26P · Sell 1x $24.5P · 10d

Net Entry $50 Debit
T+5d @ -5% Drop +$45 (+91%)
Max Risk / Buffer $50 Capped
5d Edge & Liquidity 1.1x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BAX Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $13.4B market capitalization and 7.6% operating margin.
OpEx & R&D Reinvestment 25.8% of Rev ($3.00B)
90D Engineering Disclosures 0 Published
LYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BAX vs LYRA Key Questions & Quantitative Answers

As of Nov 17, 2026, Baxter International Inc. (BAX) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BAX carries a Unified Composite Score of 46.5/100 (HOLD) at $25.83 (12.5x Forward P/E, 7.6% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin). Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. BAX 46.5/100 HOLD), BAX captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (7.6% vs. -25032.0% operating margin) and revenue trajectory (+5.0% vs. -87.2% YoY). Technical & Structure Timing Caution: BAX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.2); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BAX leads the Growth & Scale pillar: BAX posts +5.0% YoY revenue growth and +36.8% YoY earnings growth on $11.6B TTM revenue (33.4% gross margin, 7.6% operating margin), compared with LYRA at -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BAX cumulative revenue shifted +1.3% while LYRA shifted N/A. In operating R&D and SG&A reinvestment, BAX deploys 25.8% of Rev ($3.00B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LYRA.

BAX screens cheaper on headline valuation multiples. BAX trades at 12.5x Forward P/E, 12.2x Trailing P/E, N/M PEG, and 1.7x EV/Revenue (9.8% FCF margin), whereas LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BAX (-9.0% ROE) versus LYRA (-404.5% ROE) capital efficiency.

In options market volatility and institutional positioning, BAX carries 48.4% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.15x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.95β · 47% Vol realized risk). By comparison, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.